Yasutsuna Sasaki - Concepedia

Author

Yasutsuna Sasaki

Also Known As

Sasaki, Yasutsuna, Tadahiko Igarashi, Y Sasaki, Y. SASAKI, Y. Sasaki, YASUTSUNA SASAKI, YASUTSUNA SASAKI, M.D., Yasutsuna SASAKI, Yasutsuna Sasaki, Yasutsuna Sasaki, M.D.

319

Publications

5.2K

Citations

H-Index

115

Concepts

All Affiliations

Saitama Medical University Showa University National Cancer Center Hospital East National Cancer Center National Cancer Research Institute

About

Yasutsuna Sasaki is an author at Saitama Medical University specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	69	2.7K
2	Health Sciences	11	15	558
3	Biochemistry	3	3	116
4	Natural Sciences	1	1	36
5	Public Health	1	1	37

Yasutsuna Sasaki

121

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, The Lancet Oncology OncologyRandomised Phase 3Bevacizumab Versus S-1Cancer ManagementColorectal Cancer	2013	252
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani, The Lancet. Gastroenterology & hepatology Gastrointestinal OncologyMedicineAdvanced Gastric CancerPharmacologyClinical Trials	2017	215
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Journal of Thoracic Oncology Dose-escalation StudyMedicineMalignant TumorsCancer TreatmentClinical Radiation Oncology	2006	130
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer Taroh Satoh, Kyung Hee Lee, Sun Young Rha, Gastric Cancer	2014	114
Genotype‐directed, dose‐finding study of irinotecan in cancer patients with <i>UGT1A128</i> and/or <i>UGT1A16</i> polymorphisms Taroh Satoh, Takashi Ura, Yasuhide Yamada, Cancer Science Irinotecan-induced Severe NeutropeniaFixed DoseGenetic EpidemiologyHuman PolymorphismPathology	2011	103
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study Akira Sawaki, Yasuo Ohashi, Yasushi Omuro, Gastric Cancer	2011	102
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer Ken‐ichi Fujita, Wataru Yamamoto, Toshimichi Miya, Cancer Chemotherapy and Pharmacology Oncogenic AgentMedicinePharmacologyAbcb1 GenotypesPathology	2009	102
Pharmacokinetics of (glycolato-0,0?)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin Yasutsuna Sasaki, Tomohide Tamura, Kenji Eguchi, Cancer Chemotherapy and Pharmacology Medicinal ChemistryOncology-Diammine PlatinumMedicineNew Platinum Derivative	1989	97
Pharmacogenetic impact of polymorphisms in the coding region of the <i>UGT1A1</i> gene on SN‐38 glucuronidation in Japanese patients with cancer Kazuhiro Araki, Ken‐ichi Fujita, Fumio Nagashima, Cancer Science	2006	91
Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay Yuka Matsushima, Fumihiko Kanzawa, Akio Hoshi, Cancer Chemotherapy and Pharmacology OncologyPreclinical Drug EvaluationChemoprevention StrategyMedicineClonogenic Assay	1985	87

Page 1